Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Protagonist partners IBD compound PTG200 with Janssen Biotech; deal expanded

Executive Summary

In a potential $990mm deal, Protagonist Therapeutics Inc. is licensing Janssen Biotech Inc. exclusive global rights to develop, manufacture, and commercialize its PTG200 and related interleukin-23 receptor antagonists for all indications including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Marketing
    • Includes Royalty or Profit Split Information
    • Manufacturing or Supply
    • R&D and Marketing (Licensing)

Related Companies